Epperla N, Li A, Logan B, Fretham C, Chhabra S, Aljurf M, et al. Incidence, risk factors for and outcomes of transplant-associated thrombotic microangiopathy. Br J Haematol. 2020;189:1171–81.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Matsui H, Arai Y, Imoto H, Mitsuyoshi T, Tamura N, Kondo T, et al. Risk factors and appropriate therapeutic strategies for thrombotic microangiopathy after allogeneic HSCT. Blood Adv. 2020;4:3169–79.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jodele S, Davies SM, Lane A, Khoury J, Dandoy C, Goebel J, et al. Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a study in children and young adults. Blood. 2014;124:645–53.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Peffault de Latour R, Xhaard A, Fremeaux-Bacchi V, Coppo P, Fischer AM, Helley D, et al. Successful use of eculizumab in a patient with post-transplant thrombotic microangiopathy. Br J Haematol. 2013;161:279–80.

Article  PubMed  Google Scholar 

de Fontbrune FS, Galambrun C, Sirvent A, Huynh A, Faguer S, Nguyen S, et al. Use of eculizumab in patients with allogeneic stem cell transplant-associated thrombotic microangiopathy: a study from the SFGM-TC. Transplantation. 2015;99:1953–9.

Article  PubMed  Google Scholar 

Zhang R, Zhou M, Qi J, Miao W, Zhang Z, Wu D, et al. Efficacy and safety of eculizumab in the treatment of transplant-associated thrombotic microangiopathy: a systematic review and meta-analysis. Front Immunol. 2020;11:564647.

Article  CAS  PubMed  Google Scholar 

Cho BS, Yahng SA, Lee SE, Eom KS, Kim YJ, Kim HJ, et al. Validation of recently proposed consensus criteria for thrombotic microangiopathy after allogeneic hematopoietic stem-cell transplantation. Transplantation. 2010;90:918–26.

Article  CAS  PubMed  Google Scholar 

Jodele S, Dandoy CE, Danziger-Isakov L, Myers KC, El-Bietar J, Nelson A, et al. Terminal complement blockade after hematopoietic stem cell transplantation is safe without meningococcal vaccination. Biol Blood Marrow Transpl. 2016;22:1337–40.

Article  Google Scholar 

Jodele S, Fukuda T, Mizuno K, Vinks AA, Laskin BL, Goebel J, et al. Variable eculizumab clearance requires pharmacodynamic monitoring to optimize therapy for thrombotic microangiopathy after hematopoietic stem cell transplantation. Biol Blood Marrow Transpl. 2016;22:307–15.

Article  CAS  Google Scholar 

Jarmoliński T, Rosa M, Puziewicz-Zmonarska A, Kałwak K. Short course of eculizumab may be effective in dialysis-dependent transplantation-associated thrombotic microangiopathy after hematopoietic stem cell transplantation: a case report. Transpl Proc. 2020;52:2544–7.

Article  Google Scholar 

Ho VT, Cutler C, Carter S, Martin P, Adams R, Horowitz M, et al. Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation. Biol Blood Marrow Transpl. 2005;11:571–5.

Article  Google Scholar 

Au WY, Ma ES, Lee TL, Ha SY, Fung AT, Lie AKW, et al. Successful treatment of thrombotic microangiopathy after haematopoietic stem cell transplantation with rituximab. Br J Haematol. 2007;137:475–8.

Article  CAS  PubMed  Google Scholar